Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer - November 01, 2021

PDF +
Supplementary
Material

XML

Immunotherapy biomarkers

Original research

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Chen P, Zhang L, Zhang W, et al

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer

Journal for ImmunoTherapy of Cancer 2020;8:e001391. doi: 10.1136/jitc-2020-001391